| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184520 | Gynecologic Oncology | 2013 | 5 Pages |
Abstract
Although patients with wild-type TP53 ovarian cancer were rare in the TCGA high grade ovarian serous carcinomas cohort, these patients appeared to have a poorer survival and were more chemoresistant than those with mutated TP53. Differentially expressed genes in these TP53 wild-type tumors may provide insight in the molecular mechanism in chemotherapy resistance.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Kwong-Kwok Wong, Daisy I. Izaguirre, Suet-Yan Kwan, Erin R. King, Michael T. Deavers, Anil K. Sood, Samuel C. Mok, David M. Gershenson,